Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2018

Open Access 01-11-2018 | Original Article

Case–Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus

Authors: Yue Li, Hui Xu, Tao Xu, Meng Xiao, Hao Tang, Dong Wu, Bei Tan, Ji Li, Hong Yang, Hong Lv, Yingchun Xu, Jiaming Qian

Published in: Digestive Diseases and Sciences | Issue 11/2018

Login to get access

Abstract

Background and Aims

Clostridium difficile infection (CDI) incidence and risk factors in patients with inflammatory bowel disease (IBD) have been extensively studied. However, data describing CDI in Chinese patients with IBD are limited. We investigated the cumulative incidence, risk factors, and outcomes of CDI in Chinese IBD patients.

Methods

We conducted a retrospective, case–control study of patients hospitalized with IBD and CDI at Peking Union Medical College Hospital from January 2010 to December 2015. CDI was diagnosed based on the presence of active symptoms and positive enzyme immunoassay-based stool test results for C. difficile toxin A or B (CDAB). Controls were selected from CDAB-negative patients with IBD and matched by age, gender, phenotypes of IBD and the same time period of CDAB testing at a 1:2 or 1:3 ratio.

Results

We identified 60 (7.41%) cases of CDI among 810 patients with IBD, and 137 control cases were selected. Univariate analysis revealed that IBD patients with CDI had higher rates of concurrent corticosteroid use, proton pump inhibitor, antibiotic use, recent hospitalization, parenteral nutrition support, and cytomegalovirus (CMV) coinfection (P < 0.05). Multivariate analysis revealed that concurrent corticosteroid use (odds ratio [OR] = 6.803, 95% confidence interval [CI] = 2.901–15.954, P < 0.001) and hospitalization within 1 month (OR = 3.028, 95% CI = 1.225–7.480, P = 0.016) were associated with CDI. CMV and C. difficile coinfection (hazard ratio [HR] = 4.185, 95% CI = 1.492–11.736, P = 0.007) as well as disease severity (HR 2.070, 95% CI = 1.006–4.261, P = 0.048) were independently associated with colectomy following CDI.

Conclusions

IBD patients with concurrent corticosteroid use and recent hospitalization are at a higher risk of CDI. CMV and C. difficile coinfection is associated with poorer outcomes.
Literature
1.
go back to reference Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208.CrossRef Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–1208.CrossRef
2.
go back to reference Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–1450.CrossRef Nguyen GC, Kaplan GG, Harris ML, Brant SR. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:1443–1450.CrossRef
3.
go back to reference Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin N Am. 2009;38:711–728.CrossRef Ananthakrishnan AN, Issa M, Binion DG. Clostridium difficile and inflammatory bowel disease. Gastroenterol Clin N Am. 2009;38:711–728.CrossRef
4.
go back to reference Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–983.CrossRef Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976–983.CrossRef
5.
go back to reference Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile Infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153:430-8.e2.CrossRef Singh H, Nugent Z, Yu BN, Lix LM, Targownik LE, Bernstein CN. Higher incidence of Clostridium difficile Infection among individuals with inflammatory bowel disease. Gastroenterology. 2017;153:430-8.e2.CrossRef
6.
go back to reference Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539–1548.CrossRef Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539–1548.CrossRef
7.
go back to reference Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis. 2013;19:194–204.CrossRef Berg AM, Kelly CP, Farraye FA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis. 2013;19:194–204.CrossRef
8.
go back to reference Zhang T, Lin QY, Fei JX, et al. Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease. Sci Rep. 2016;6:29791.CrossRef Zhang T, Lin QY, Fei JX, et al. Clostridium difficile infection worsen outcome of hospitalized patients with inflammatory bowel disease. Sci Rep. 2016;6:29791.CrossRef
9.
go back to reference Gu YB, Zhang MC, Sun J, Lv KZ, Zhong J. Risk factors and clinical outcome of Clostridium difficile infection in patients with IBD: a single-center retrospective study of 260 cases in China. J Dig Dis. 2017;18:207–211.CrossRef Gu YB, Zhang MC, Sun J, Lv KZ, Zhong J. Risk factors and clinical outcome of Clostridium difficile infection in patients with IBD: a single-center retrospective study of 260 cases in China. J Dig Dis. 2017;18:207–211.CrossRef
10.
go back to reference Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.CrossRef Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041–1048.CrossRef
11.
go back to reference Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRef Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625–1629.CrossRef
12.
go back to reference Silverberg, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5a–36a.CrossRef Silverberg, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5a–36a.CrossRef
13.
go back to reference Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet (London, England). 1980;1:514.CrossRef Harvey RF, Bradshaw JM. A simple index of Crohn’s-disease activity. Lancet (London, England). 1980;1:514.CrossRef
14.
go back to reference Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210.CrossRef Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–210.CrossRef
15.
go back to reference Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:345–351. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:345–351.
16.
go back to reference Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:339–344. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2007;5:339–344.
17.
go back to reference Joshi NM, Marks IH, Crowson R, Ball D, Rampton DS. Incidence and outcome of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease in the UK. J Crohn’s Colitis. 2017;11:70–76.CrossRef Joshi NM, Marks IH, Crowson R, Ball D, Rampton DS. Incidence and outcome of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease in the UK. J Crohn’s Colitis. 2017;11:70–76.CrossRef
18.
go back to reference Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:428–441.CrossRef Goodhand JR, Alazawi W, Rampton DS. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:428–441.CrossRef
19.
go back to reference Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohn’s Colitis. 2010;4:194–198.CrossRef Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohn’s Colitis. 2010;4:194–198.CrossRef
20.
go back to reference van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, Endtz HP, van der Vorm ER, Kuijper EJ. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol. 2005;43:5338–5340.CrossRef van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ, Endtz HP, van der Vorm ER, Kuijper EJ. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol. 2005;43:5338–5340.CrossRef
21.
go back to reference van den Berg RJ, Vaessen N, Endtz HP, Schulin T, van der Vorm ER, Kuijper EJ. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J Clin Microbiol. 2007;56:36–42. van den Berg RJ, Vaessen N, Endtz HP, Schulin T, van der Vorm ER, Kuijper EJ. Evaluation of real-time PCR and conventional diagnostic methods for the detection of Clostridium difficile-associated diarrhoea in a prospective multicentre study. J Clin Microbiol. 2007;56:36–42.
22.
go back to reference Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–264.CrossRef Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009;30:253–264.CrossRef
23.
go back to reference Ananthakrishnan AN, Cagan A, Gainer VS, et al. Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39:1136–1142.CrossRef Ananthakrishnan AN, Cagan A, Gainer VS, et al. Higher plasma vitamin D is associated with reduced risk of Clostridium difficile infection in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;39:1136–1142.CrossRef
24.
go back to reference Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280:22–35.CrossRef Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol. 2012;280:22–35.CrossRef
25.
go back to reference Hing TC, Ho S, Shih DQ, et al. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut. 2013;62:1295–1305.CrossRef Hing TC, Ho S, Shih DQ, et al. The antimicrobial peptide cathelicidin modulates Clostridium difficile-associated colitis and toxin A-mediated enteritis in mice. Gut. 2013;62:1295–1305.CrossRef
26.
go back to reference Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohn’s Colitis. 2011;5:34–40.CrossRef Kariv R, Navaneethan U, Venkatesh PG, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohn’s Colitis. 2011;5:34–40.CrossRef
27.
go back to reference McCurdy JD, Enders FT, Khanna S, et al. Increased rates of Clostridium difficile infection and poor outcomes in patients with IBD with cytomegalovirus. Inflamm Bowel Dis. 2016;22:2688–2693.CrossRef McCurdy JD, Enders FT, Khanna S, et al. Increased rates of Clostridium difficile infection and poor outcomes in patients with IBD with cytomegalovirus. Inflamm Bowel Dis. 2016;22:2688–2693.CrossRef
28.
go back to reference Chan KS, Lee WY, Yu WL. Coexisting cytomegalovirus infection in immunocompetent patients with Clostridium difficile colitis. J Microbiol Immunol Infect. 2016;49:829–836.CrossRef Chan KS, Lee WY, Yu WL. Coexisting cytomegalovirus infection in immunocompetent patients with Clostridium difficile colitis. J Microbiol Immunol Infect. 2016;49:829–836.CrossRef
Metadata
Title
Case–Control Study of Inflammatory Bowel Disease Patients with and without Clostridium difficile Infection and Poor Outcomes in Patients Coinfected with C. difficile and Cytomegalovirus
Authors
Yue Li
Hui Xu
Tao Xu
Meng Xiao
Hao Tang
Dong Wu
Bei Tan
Ji Li
Hong Yang
Hong Lv
Yingchun Xu
Jiaming Qian
Publication date
01-11-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5230-1

Other articles of this Issue 11/2018

Digestive Diseases and Sciences 11/2018 Go to the issue